Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of community pharmacy in the prevention of cardiovascular disease in minority ethnic groups in the UK including barriers and facilitators: a mixed-methods systematic review.

BMJ open·2026
Same author

Real-world changes in lipid-lowering therapy use and LDL-C goal attainment in high and very high cardiovascular risk patients in the UK: a secondary analysis of the European SANTORINI study 1-year follow-up.

BMJ open·2026
Same author

Optimizing lipid-lowering therapy for acute coronary syndrome using a decision support system: insights from a cluster randomized trial.

European heart journal. Digital health·2026
Same author

Advancing Cardiovascular, Kidney, and Metabolic Medicine: A Narrative Review of Insights and Innovations for the Future.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2025
Same author

Letter to the editor re: Racial bias in CCT article.

Journal of cardiovascular computed tomography·2025
Same author

The Use of Apabetalone in Reducing Cardiovascular Outcomes, Based on the Current Evidence and Trials.

European cardiology·2025

Related Experiment Video

Updated: Jun 23, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Drug-eluting stents: a comprehensive appraisal.

Mehmood Butt1, Derek Connolly, Gregory Y H Lip

  • 1University Department of Medicine, City Hospital, Birmingham, B18 7QH, UK.

Future Cardiology
|April 18, 2009
PubMed
Summary

Drug-eluting stents (DES) have significantly improved cardiovascular medicine by reducing restenosis compared to bare metal stents. Ongoing innovations aim to further enhance stent performance and patient outcomes in coronary artery disease management.

More Related Videos

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents
06:55

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016

Related Experiment Videos

Last Updated: Jun 23, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents
06:55

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Biomaterials Science

Background:

  • Percutaneous coronary interventions, including angioplasty and stenting, have transformed cardiovascular disease management.
  • Long-term stent use faces challenges from in-stent restenosis and stent thrombosis.
  • Drug-eluting stents (DES) were developed to overcome the significant problem of restenosis.

Purpose of the Study:

  • To review the evolution and efficacy of coronary stents, particularly drug-eluting stents (DES).
  • To discuss the advantages of DES over bare metal stents in various patient populations.
  • To explore current and future advancements in stent technology for improved clinical outcomes.

Main Methods:

  • Review of randomized trials comparing DES with bare metal stents.
  • Analysis of clinical data on stent thrombosis and restenosis rates.
  • Discussion of emerging stent technologies, including newer drug-eluting platforms and antibody-coated stents.

Main Results:

  • DES demonstrate superior efficacy compared to bare metal stents in elective PCI, acute coronary syndromes, and diabetic patients.
  • While dual-antiplatelet therapy reduced stent thrombosis, restenosis remains a concern addressed by DES.
  • Newer generation DES with various drugs (everolimus, zotarolimus, tacrolimus) and improved platforms show enhanced performance.

Conclusions:

  • Drug-eluting stents represent a significant advancement in managing coronary artery disease, offering improved outcomes over bare metal stents.
  • While effective, the use of DES in venous bypass graft disease requires further investigation.
  • Future stent developments, including antibody-coated stents, hold promise for further reducing restenosis through enhanced endothelialization.